Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23299307 | 0.89 | SCN5A (0.46) | SCN5ASCN9ASCN10A | |
| SCHEMBL16330807 | 0.84 | SCN5A (0.52) | SCN5ASCN9ASCN10A | |
| SCHEMBL9082255 | 0.83 | SCN5A (0.46) | SCN5ASCN9ASCN10A | |
| SCHEMBL23277004 | 0.82 | SMN1; SMN2 (0.51) | SCN5ASCN9ASCN10A | |
| SCHEMBL9754189 | 0.81 | SCN5A (0.47) | SCN5ASCN9ASCN10A | |
| SCHEMBL23299303 | 0.81 | SCN5A (0.47) | SCN5ASCN9ASCN10A | |
| Hydrochloric Acid SCHEMBL3165912 | 0.80 | SCN5A (0.44) | SCN5ASCN9ASCN10A | |
| SCHEMBL2016482 | 0.79 | SCN5A (0.48) | SCN5ASCN9ASCN10A | |
| SCHEMBL4126064 | 0.79 | SCN5A (0.46) | SCN5ASCN9ASCN10A | |
| SCHEMBL23299310 | 0.79 | SCN5A (0.46) | SCN5ASCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105808-A | Propofol compound and preparation method and application thereof | 深圳市爱卫德为生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | IL4I1, SLC7A1, GOT1 | SCN5A 2170/4885SCN9A 3914/4885SCN10A 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.